Vemurafenib vs. Combination Dabrafenib/Trametinib

At present, two selective BRAF inhibitors (dabrafenib and vemurafenib) and one MEK inhibitor (trametinib) are FDA-approved for treating stage IV BRAFV600E -mutated metastatic melanoma. Single-agent dabrafenib but not vemurafenib has been tested against combination dabrafenib/trametinib. Vemurafenib monotherapy is in current use; these investigators studied its efficacy relative to combination dabrafenib/trametinib. A total of 704 patients were randomized to receive either oral …